Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections

September 18, 2018

Top-line results for SURE 2 and SURE 3 expected in the second half of 2019, with new drug application (NDA) submissions anticipated by the end of 2019
More »

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

September 17, 2018

U.S. Commercial Launch of Cash-Pay Product Anticipated in Mid-2019
More »

Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

August 9, 2018

Top-line results expected in 2H 2019 and NDA submission anticipated by the end of 2019
More »